Gilead Sciences, Inc. (NASDAQ:GILD) has added another treatment to its HIV portfolio with the FDA approval of Bixlenvo, a once-daily pill for adults whose infec...
Market Samachar is a news aggregator. This article was originally published by insidermonkey.com. Tap the button above to read the full story on their site.